Seeking Alpha

David Greene's  Instablog

David Greene
Send Message
Trading and investing full time for personal account and consulting with a money manager firm with assets of over $55 Million. Worked on Wall Street for 14 years at two wirehouses and one boutique investment banking firm. Investment discipline includes taking advantage of Wall Street's tendency... More
My blog:
sirf.com
  • Celldex Therapeutics' ASCO Abstracts With Brain Cancer Trial Confirming Previous Trial Results 0 comments
    May 21, 2010 8:40 AM | about stocks: PFE, CLDX, ABIO, ABT, ADLR, AFFX, ARIA, ARYX, BAX, BCR, BDX, BSX, CELG, CMN, CNMD, CTIC, CTT-RETIRED, CYBX, DCTH, DNDN, ENZ, ETRM, GE, GILD, GNVC, GSK, HAE, IART, IBPI, IRIX, JNJ, KOOL, MAKO, MDT, MLNM, NVS, PDLI, PGNX, PHG, PMTI, RDNT, RTN, SOMX, SQNM, STJ, STS, SYK, VOLC, VVUS, WYE

    Celldex Therapeutics Inc. (Nasdaq:CLDX) has a full plate at the American Society of Clinical Oncology (OTC:ASCO) Annual Meeting June 5-8--with four abstracts being presented:

    CDX-011 in Advanced Melanoma
    CDX-011 in Breast Cancer
    CDX-1307 in Muscle-invasive Bladder Cancer --Trials in Progress Poster Session

    and the most awaited "Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM)".

    The data
    showed that CLDX's brain cancer vaccine exhibited efficacy with 70% of patients surviving with no progression of cancer tumor growth 5.5 months after being treated.  Looked at another way, the 70% rate is about 40% better versus standard care. The trial protocol involved a particular challenge in clinical trials--patients recruited for the trial had to have completed their chemotherapy without their brain cancer tumor progressing, which usually resulted in a two to three month delay from starting. As the abstract conclusions stated,  "Vaccination with PF-04948568 was well tolerated in combination with maintenance TMZ in pts with newly diagnosed, fully resected GBM. PFR of 70% at 5.5 months reported from this multicenter experience is similar to that reported from the previous Duke/MDACC trial. Difficulties retaining control arm pts in this open label US trial, suggest that additional study of the vaccine would require a placebo controlled trial." So the results are consistent with the previous trial, but did not offer any better results. One patient exhibited an allergic reaction which necessitated the discontinuation of that patient from receiving CDX-110. 

    Pfizer (NYSE:PFE), Celldex's partner in developing CDX-110, and CLDX will be conducting a randomized  Phase III study with international clinical sites later.

    On a more general note, with the turmoil in the markets in general, it will be difficult to assess how investors react to the posted ASCO abstracts today (May 21). Investors that may have taken positions in companies that were to present at ASCO may make decisions based on preservation of capital versus holding for the ASCO meeting, regardless the strength of any clinical results.



    Disclosure: No positions
Back To David Greene's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • European markets cratered on Labor Day, setting the stage for a 250-300 point drop in the DOW when traders return on Tuesday.
    Sep 5, 2011
  • Competitive Technologies (CTTC, $1.75) for continued strength after chronic pain technology is highlighted on two TV morning shows tomorrow.
    Mar 14, 2011
  • CTT-RETIRED soared today on news showing influential professional interest and sponsorship of the company's pain management therapy technology.
    Apr 13, 2010
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.